I usually tweet about #obesity but since I recently had a pt with type 2 #diabetes go from 100 units/d insulin to 0 with tirzepatide, this is a good time to review #insulin management when you start a GLP1 / GIP
TLDR:
If you're starting a GLP1 / GIP for a pt with #diabetes treated with insulin...
👉⬇️ Basal insulin by 20% if A1c<8
👉Basal insulin need will ~⬇️15%
👉Prandial insulin need will ~⬇️30%
👉Remember RCTs were conducted with lower doses of GLP1s than currently available
7/7
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Satiation is the feeling of fullness WITHIN a meal while satiety is the feeling of fullness IN BETWEEN meals
Even though current meds like GLP1s seem to affect both, it’s an impt distinction especially when some peptides (eg, amylin)
may only effect satiation (⬇️meal size) and not satiety (change meal frequency)
[btw This study was an intracerebral injection of calcitonin into male rats and calcitonin is an agonist at the amylin receptor in the ventral tegmental area]
EMPA-KIDNEY is unique because it enrolled GFR 20-45 *without* proteinuria whereas others (DAPA CKD, CANVAS) enrolled pts with CKD+proteinuria, though DAPA-CKD conducted a subgroup analysis for UACR < and > 1000
The primary outcome was a composite of progression of #kidney disease (defined as #ESRD, a sustained decrease in eGFR to <10, a sustained decrease in eGFR of ≥40% from baseline, or death
from #renal causes) or death from #cardiovascular causes